|Articles|October 16, 2020
Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides
Author(s)Agilent
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
VectorY Doses First Patient in TDP-43–Targeting ALS Trial
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Ivonescimab Breakthrough Designation Highlights Progress in BTC Treatment
4
Speed-to-IND Starts with Toxicology: A Rapid-Fire Q&A with Lonza
5